Vanda Pharmaceuticals (VNDA) Tops Q4 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Revenue Growth %: +23.2%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.36, $0.35 better than the analyst estimate of $0.01. Revenue for the quarter came in at $53.04 million versus the consensus estimate of $51.7 million.
GUIDANCE:
2019 Financial Guidance
Vanda expects to achieve the following financial objectives in 2019:
Full Year 2019 Guidance | |
Combined net product sales from both HETLIOZ® and Fanapt® | $215 to $225 million |
HETLIOZ® net product sales | $137 to $143 million |
Fanapt® net product sales | $78 to $82 million |
Year-end 2019 Cash | Greater than $260 million |
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- HIMS jumps 7% on peptide tailwind but Citi sees 17% downside from here
- Lamb Weston (LW) Tops Q1 EPS by 15c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
